gene expression arrays
The 20-year study showed the test provided an accurate assessment of the risk of long-term metastases and mortality for patients with localized prostate cancer.
Allarity Therapeutics Seeks FDA Premarket Approval for Prediction Tool as CDx for Dovitinib
The DRP would be used to identify kidney cancer patients likely to benefit from dovitinib, a repurposed TKI for which Allarity plans to file an NDA this year.
FLEX will include full transcriptome data paired with 800 data points from 10,000 patients, offering researchers the chance to study diverse patient subsets.
Agendia, Paige Partner to Codevelop New Assays Using MammaPrint, BluePrint Signatures
The companies aim to create new products enabling faster access to predictive information used in treatment planning for patients with breast cancer.
At the American Society of Clinical Oncology's virtual meeting, investigators presented two new studies of BluePrint classification patterns.